avosentan   Click here for help

GtoPdb Ligand ID: 8260

Synonyms: Ro 67-0565 | SPP-301
Compound class: Synthetic organic
Comment: Avosentan is an endothelin A antagonist indicated for diabetic nephropathy. Speedel licensed SPP301 from Hoffmann-La Roche in 2000.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 133.8
Molecular weight 479.13
XLogP 2.76
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cn1)C)c1ccncc1
Isomeric SMILES COc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cn1)C)c1ccncc1
InChI InChI=1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)
InChI Key YBWLTKFZAOSWSM-UHFFFAOYSA-N
References
1. Breu, V. et al.. (2003)
Heterocyclic sulfonamides.
Patent number: US6521631. Assignee: Hoffmann-La Roche. Priority date: 13/03/2015. Publication date: 18/02/2003.
2. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, ASCEND Study Group. (2010)
Avosentan for overt diabetic nephropathy.
J Am Soc Nephrol, 21 (3): 527-35. [PMID:20167702]